MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

8.620 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41
Open 8.620
Bid (Size) 8.200 (100)
Ask (Size) 8.830 (200)
Prev. Close 8.620
Today's Range 8.620 - 8.620
52wk Range 4.445 - 14.06
Shares Outstanding 52,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan 
From Emergent BioSolutions
Via GlobeNewswire

Performance

YTD
-31.1%
-31.1%
1 Month
+6.7%
+6.7%
3 Month
-21.3%
-21.3%
6 Month
-8.3%
-8.3%
1 Year
+86.6%
+86.6%

More News

Read More
News headline image
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Inc (NYSE:EBS) Shares Tumble on Weak Q4 Results and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? ↗
Via Stocktwits
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Why Did EBS Stock Fall 13% Today? ↗
Via Stocktwits
Topics Law Enforcement Lawsuit
News headline image
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
From Emergent BioSolutions
Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?
Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.
What exchange does Emergent BioSolutions Inc. Common Stock trade on?
Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?
The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange
What is the current price of Emergent BioSolutions Inc. Common Stock?
The current price of Emergent BioSolutions Inc. Common Stock is 8.620
When was Emergent BioSolutions Inc. Common Stock last traded?
The last trade of Emergent BioSolutions Inc. Common Stock was at 04/16/26 07:00 PM ET
What is the market capitalization of Emergent BioSolutions Inc. Common Stock?
The market capitalization of Emergent BioSolutions Inc. Common Stock is 454.27M
How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?
Emergent BioSolutions Inc. Common Stock has 454M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story